Skip to main content

Table 5 Multivariable-adjusted mean changes in cardiovascular disease risk factors (95% CI) over 6ā€‰years of follow-up, according to quartiles of sedentary time and meeting guidelines for moderate-to-vigorous physical activity among men and women ā€“ No exclusionsa

From: Are sedentary behavior and physical activity independently associated with cardiometabolic benefits? The Hispanic Community Health Study/Study of Latinos

Change in CVD risk factors

Sedentary time

P of inter-action

MVPA guidelinesb

P of inter-action

Quartile 1

(0.8ā€“10.8ā€‰h)

Quartile 2

(10.8ā€“12.0ā€‰h)

Quartile 3

(12.0ā€“13.0ā€‰h)

Quartile 4

(13.0ā€“16.0ā€‰h)

Not meet

Meet

BMI, kg/m2

Ā Ā Ā Ā 

0.59

Ā Ā 

0.99

ā€ƒWomen

0.68 (0.40, 0.95)

0.85 (0.63, 1.08)

0.74 (0.50, 0.98)

0.83 (0.56, 1.09)

Ā 

0.73 (0.57, 0.90)

0.86 (0.65, 1.07)

Ā 

ā€ƒMen

0.60 (0.33, 0.87)

0.75 (0.42, 1.08)

0.32 (0.04, 0.60)

0.61 (0.33, 0.89)

Ā 

0.51 (0.31, 0.70)

0.63 (0.40, 0.86)

Ā 

Waist circumference, cm

Ā Ā Ā Ā 

0.08

Ā Ā 

0.79

ā€ƒWomen

1.52 (0.76, 2.28)

1.64 (0.88, 2.40)

1.92 (1.27, 2.57)

2.26 (1.49, 3.03)

Ā 

1.87 (1.36, 2.38)

1.84 (1.30, 2.37)

Ā 

ā€ƒMen

3.12 (2.37, 3.88)

3.03 (2.16, 3.90)

1.64 (0.68, 2.59)

2.88 (2.02, 3.73)

Ā 

2.64 (2.07, 3.22)

2.75 (2.09, 3.41)

Ā 

Systolic BP, mmHg

Ā Ā Ā Ā 

0.43

Ā Ā 

0.67

ā€ƒWomen

āˆ’0.00 (āˆ’1.10, 1.09)

0.96 (āˆ’0.14, 2.05)

0.50 (āˆ’ā€‰0.67, 1.68)

0.58 (āˆ’ā€‰0.54, 1.70)

Ā 

0.51 (āˆ’ā€‰0.22, 1.24)

0.60 (āˆ’ā€‰0.37, 1.57)

Ā 

ā€ƒMen

1.77 (0.59, 2.94)

1.88 (0.62, 3.13)

1.41 (0.08, 2.75)

0.48 (āˆ’ā€‰0.76, 1.72)

Ā 

1.55 (0.46, 2.64)

1.28 (0.50, 2.06)

Ā 

Diastolic BP, mmHg

Ā Ā Ā Ā 

0.72

Ā Ā 

0.99

ā€ƒWomen

āˆ’0.49 (āˆ’1.36, 0.38)

0.40 (āˆ’0.38, 1.18)

āˆ’ā€‰0.21 (āˆ’ā€‰0.98, 0.55)

āˆ’0.48 (āˆ’ā€‰1.34, 0.38)

Ā 

āˆ’ā€‰0.25 (āˆ’ā€‰0.79, 0.29)

āˆ’0.04 (āˆ’ā€‰0.79, 0.72)

Ā 

ā€ƒMen

0.58 (āˆ’0.31, 1.48)

0.64 (āˆ’ā€‰0.31, 1.59)

0.32 (āˆ’ā€‰0.76, 1.39)

āˆ’0.22 (āˆ’ā€‰1.24, 0.81)

Ā 

0.22 (āˆ’ā€‰0.56, 1.00)

0.42 (āˆ’ā€‰0.24, 1.08)

Ā 

LDL-cholesterol, mg/dl

Ā Ā Ā Ā 

0.34

Ā Ā 

0.15

ā€ƒWomen

āˆ’4.62 (āˆ’6.73, āˆ’2.51)

āˆ’4.48 (āˆ’6.54, āˆ’2.41)

āˆ’3.63 (āˆ’5.97, āˆ’ā€‰1.30)

āˆ’5.39 (āˆ’7.57, āˆ’3.20)

Ā 

āˆ’3.74 (āˆ’ā€‰5.34, āˆ’ā€‰2.13)

āˆ’6.01 (āˆ’ā€‰7.96, āˆ’ā€‰4.05)

Ā 

ā€ƒMen

āˆ’ā€‰6.38 (āˆ’8.88, āˆ’ā€‰3.89)

āˆ’3.18 (āˆ’ā€‰6.77, 0.41)

āˆ’5.18 (āˆ’ā€‰8.34, āˆ’ā€‰2.02)

āˆ’ā€‰3.94 (āˆ’ā€‰7.07, āˆ’ā€‰0.82)

Ā 

āˆ’5.03 (āˆ’7.15, āˆ’ā€‰2.91)

āˆ’ā€‰4.57 (āˆ’ā€‰6.75, āˆ’ā€‰2.39)

Ā 

HDL-cholesterol, mg/dl

Ā Ā Ā Ā 

0.82

Ā Ā 

0.30

ā€ƒWomen

2.61 (1.67, 3.55)

2.02 (1.30, 2.75)

2.55 (1.64, 3.46)

1.82 (0.94, 2.71)

Ā 

2.25 (1.68, 2.82)

2.18 (1.44, 2.92)

Ā 

ā€ƒMen

0.65 (āˆ’ā€‰0.33, 1.64)

0.58 (āˆ’ā€‰0.42, 1.58)

1.48 (0.38, 2.59)

0.49 (āˆ’ā€‰0.46, 1.43)

Ā 

1.21 (0.47, 1.94)

0.45 (āˆ’ā€‰0.34, 1.25)

Ā 

Triglycerides, mg/dlc

Ā Ā Ā Ā 

0.09

Ā Ā 

0.09

ā€ƒWomen

0.92 (0.88, 0.96)

0.91 (0.87, 0.95)

0.96 (0.92, 1.00)

0.95 (0.91, 0.99)

Ā 

0.94 (0.91, 0.96)

0.93 (0.89, 0.97)

Ā 

ā€ƒMen

0.98 (0.93, 1.03)

0.95 (0.91, 1.00)

0.92 (0.87, 0.97)

0.95 (0.91, 1.00)

Ā 

0.93 (0.89, 0.96)

0.97 (0.94, 1.01)

Ā 

Fasting glucose, mg/dl

Ā Ā Ā Ā 

0.62

Ā Ā 

0.23

ā€ƒWomen

3.43 (2.04, 4.83)

3.55 (2.46, 4.64)

4.18 (2.78, 5.59)

4.90 (3.66, 6.14)

Ā 

4.56 (3.68, 5.43)

3.06 (2.12, 4.00)

Ā 

ā€ƒMen

3.87 (2.54, 5.20)

4.70 (3.10, 6.31)

4.40 (2.96, 5.85)

4.22 (2.48, 5.97)

Ā 

4.52 (3.37, 5.68)

4.11 (3.08, 5.14)

Ā 

2-h glucose, mg/dl

Ā Ā Ā Ā 

0.31

Ā Ā 

0.56

ā€ƒWomen

8.13 (4.59, 11.68)

9.00 (6.03, 11.97)

8.38 (5.11, 11.65)

13.24 (9.82, 16.66)

Ā 

10.08 (8.02, 12.15)

8.91 (6.26, 11.57)

Ā 

ā€ƒMen

5.95 (2.61, 9.29)

7.40 (3.20, 11.59)

6.78 (1.31, 12.24)

6.13 (2.43, 9.83)

Ā 

6.48 (3.54, 9.41)

6.65 (3.85, 9.46)

Ā 

HbA1c, mg/dl

Ā Ā Ā Ā 

0.48

Ā Ā 

0.45

ā€ƒWomen

0.19 (0.15, 0.23)

0.18 (0.15, 0.21)

0.19 (0.15, 0.22)

0.17 (0.14, 0.20)

Ā 

0.18 (0.16, 0.20)

0.19 (0.15, 0.22)

Ā 

ā€ƒMen

0.18 (0.14, 0.22)

0.19 (0.14, 0.23)

0.13 (0.09, 0.17)

0.15 (0.11, 0.20)

Ā 

0.15 (0.12, 0.18)

0.18 (0.14, 0.21)

Ā 

Fasting insulin, mU/Lc

Ā Ā Ā Ā 

0.14

Ā Ā 

0.01

ā€ƒWomen

1.16 (1.10, 1.22)

1.20 (1.14, 1.26)

1.23 (1.18, 1.29)

1.25 (1.20, 1.31)

Ā 

1.25 (1.21, 1.29)

1.15 (1.11, 1.20)

Ā 

ā€ƒMen

1.19 (1.13, 1.26)

1.26 (1.17, 1.35)

1.16 (1.07, 1.25)

1.20 (1.13, 1.27)

Ā 

1.19 (1.14, 1.24)

1.21 (1.15, 1.27)

Ā 

HOMA-IRc

Ā Ā Ā Ā 

0.21

Ā Ā 

0.01

ā€ƒWomen

1.21 (1.14, 1.28)

1.23 (1.16, 1.30)

1.27 (1.22, 1.33)

1.30 (1.23, 1.36)

Ā 

1.29 (1.24, 1.33)

1.20 (1.14, 1.25)

Ā 

ā€ƒMen

1.25 (1.18, 1.33)

1.32 (1.22, 1.43)

1.22 (1.13, 1.33)

1.27 (1.19, 1.35)

Ā 

1.25 (1.20, 1.31)

1.27 (1.21, 1.34)

Ā 
  1. aAll models adjusted for sex, use of medications that affect the dependent variable at baseline and/or visit2, baseline levels of the dependent variable, and elapsed time between visits, household income, education, employment status, Hispanic/Latino background, field center, and nativity status, smoking, alcohol consumption, health insurance status, healthcare utilization, self-reported health, diet quality (all assessed at baseline), change in health insurance coverage, BMI and waist-to-hip ratio (except for change in BMI and waist circumference as outcomes). bMeeting 2018 physical activity guidelines defined using measured activity scaled to 7 days of accelerometer wear as 150 minutes/week moderate intensity physical activity, 75 minutes/week vigorous intensity activity, or an equivalent combination of both. c Geometric means (95% CI) presented for triglycerides, fasting insulin, HOMA-IR; significant findings <0.05 bolded